Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Via News Knowledge File

Eli Lilly and Company

organization80% conf.·synced Aug 16, 2026

Pharmaceutical company with gene therapy licensing deal with REGENXBIO

52
sourced metrics
1271
relationships
20
stated objectives
3
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap
1110951953830USD
Aug 14, 2026reference only
Stock Return Ytd
9.2%
Aug 14, 2026reference only
Stock Price
1180.16USD
Aug 14, 2026reference only
Price 52 Week Low
695.33USD
Aug 14, 2026reference only
Price 52 Week High
1235.56USD
Aug 14, 2026reference only
Shares Outstanding
941357065.0shares
Aug 3, 2026reference only
Oral Presentations
3count
Jul 9, 2026source
Abstracts Presented
16count
Jul 9, 2026source
Poster Presentations
13count
Jul 9, 2026source
Years Of Alzheimers Research Commitment
35years
Jul 9, 2026source
Cost Of Revenue
3268000000.0USD
Jun 30, 2026reference only
Revenue
22974000000.0USD
Jun 30, 2026reference only
Eps
7.94USD_per_share
Jun 30, 2026reference only
Net Income
7095000000.0USD
Jun 30, 2026reference only
Total Assets
142283000000.0USD
Jun 30, 2026reference only
Cash
8950000000.0USD
Jun 30, 2026reference only
Stockholders Equity
33879000000.0USD
Jun 30, 2026reference only
Acquisition Count
11count
Jun 17, 2026source

Stated objectives

Obtain U.S. regulatory approval for Inluriyo in combination with abemaciclib for ESR1-mutated MBC

source
stated

Advance LY4064809/STX-478 from Phase 1/2 to Phase 3 trial for PIK3CA-mutant HR+, HER2- advanced breast cancer

source
stated

Demonstrate overall survival benefit, progression-free survival, and time to chemotherapy improvements in EMBER-3 trial for ESR1-mutated breast cancer

source
stated

Show sustained IDFS/DRFS improvements and OS prolongation in monarchE trial across nodal status subgroups

source
stated

Translate biologic conviction into meaningful progress by addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K

source
stated

Demonstrate non-inferiority of pirtobrutinib versus ibrutinib on overall response rate in CLL/SLL patients

source
target: non-inferiority on ORR stated

Complete formal PFS analysis testing for superiority of pirtobrutinib

source
target: superiority on PFS stated

Verify and describe clinical benefit of Jaypirca in confirmatory trials to maintain accelerated approval status

source
target: clinical benefit verification stated

Demonstrate pirtobrutinib's potential role across treatment settings and B-cell malignancies through development program

source
stated

Receive regulatory approvals for pirtobrutinib in earlier disease settings to expand treatment options for patients

source
target: regulatory approval by 2026-01-01 00:00:00stated

Relationship graph · 1271 connections

Developed by
511
Competes with
198
Employs
82
Covered by
57
acquired by
50
regulates
45
headquartered in
41
located in
27
board member of
Dave Ricks

Via News coverage

Novo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI-Native Partner
June 19, 2026
Novo Nordisk Stock Surges 24.9% in 30 Days as AI Reshapes European Drug Discovery
May 27, 2026
Novo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Closes Internal Unit
May 16, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →